Efficacy of a recombinant turkey herpesvirus (H9) vaccine against H9N2 avian influenza virus in chickens with maternal-derived antibodies
Frontiers in Microbiology · 26.01.2023 · 13
DOI: 10.3389/fmicb.2022.1107975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 26.01.2023. Verfasst von Xue Pan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council.
Abstract (Originalsprache)
Although vaccines have been widely used for many years, they have failed to control H9N2 avian influenza virus (AIV) in the field in China. The high level of maternal-derived antibodies (MDAs) against H9N2 virus contributes to the H9N2 influenza vaccine failure in poultry. The study aimed to generate a new vaccine to overcome MDAs interference in H9N2 vaccination in chickens. We used turkey herpesvirus (HVT) as a vaccine vector to express H9 hemagglutinin (HA) proteins. The recombinant HVT expressing H9 HA proteins (rHVT-H9) was successfully generated and characterized in primary chicken embryonic fibroblasts (CEFs). Western blot and indirect immunofluorescence assay (IFA) showed that the rHVT-H9 consistently expressed HA proteins. In addition, the rHVT-H9 had similar growth kinetics to the parent HVT. Preliminary animal experiments showed that compared to the conventional inactivated whole virus (IWV) vaccine, the rHVT-H9 stimulated robust humoral immunity in chickens with passively transferred antibodies (PTAs) that were used to mimic MDAs. Transmission experiments showed that the rHVT-H9 induced both humoral and cellular immunity in chickens with PTAs. Furthermore, we used mathematical models to quantify the vaccine’s efficacy in preventing the transmission of H9N2 AIV. The results showed that the rHVT-H9 reduced the virus shedding period and decreased the reproduction ratio (R) value in chickens with PTAs after homologous challenge. However, the vaccination in this trial did not yet bring R < 1. In summary, we generated a new rHVT-H9 vaccine, which stimulated strong humoral and cellular immunity, reducing virus shedding and transmission of H9N2 AIV even in the presence of PTAs in chickens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China.
- Quantitative Veterinary Epidemiology, Animal Sciences Group, Wageningen University and Research, Wageningen, Netherlands.
- Wageningen Bioveterinary Research, Wageningen University and Research, Lelystad, Netherlands.
- Host-Microbe Interactomics Group, Animal Sciences Group, Wageningen University and Research, Wageningen, Netherlands.
Förderung
- China Scholarship Council
Zitieren
APA
Pan, X., Liu, Q., Niu, S., Huang, D., Yan, D., Teng, Q., Li, X., Beerens, N., Forlenza, M., de Jong, M. C. M., & Li, Z. (2023). Efficacy of a recombinant turkey herpesvirus (H9) vaccine against H9N2 avian influenza virus in chickens with maternal-derived antibodies. Frontiers in Microbiology, 13. https://doi.org/10.3389/fmicb.2022.1107975
Vancouver
Pan X, Liu Q, Niu S, Huang D, Yan D, Teng Q, et al. Efficacy of a recombinant turkey herpesvirus (H9) vaccine against H9N2 avian influenza virus in chickens with maternal-derived antibodies. Frontiers in Microbiology. 2023;13. doi:10.3389/fmicb.2022.1107975
BibTeX
@article{Pan2023,
author = {Pan, Xue and Liu, Qinfang and Niu, Shiqi and Huang, Dongming and Yan, Dawei and Teng, Qiaoyang and Li, Xuesong and Beerens, Nancy and Forlenza, Maria and de Jong, Mart C M and Li, Zejun},
title = {Efficacy of a recombinant turkey herpesvirus (H9) vaccine against H9N2 avian influenza virus in chickens with maternal-derived antibodies},
journal = {Frontiers in Microbiology},
year = {2023},
volume = {13},
doi = {10.3389/fmicb.2022.1107975}
}
EUVIMED